Select Page

2024

Why We Need Organized Screening Programs

Em. Prof. Hendrik Van Poppel argues for the necessity of organized screening programs for prostate cancer, underscoring the impact of early detection, which can identify the disease at an earlier, more treatable stage.

Dr. Van Poppel presents compelling evidence from studies and clinical trials demonstrating that systematic screening leads to earlier diagnoses, which correlates with better survival rates. He critiques the current state of prostate cancer screening, which is often opportunistic and inconsistent, leading to disparities in early detection and treatment outcomes.

He highlights the importance of establishing clear guidelines and protocols to optimize the efficiency and effectiveness of these programs. Dr. Van Poppel advocates for the use of advanced diagnostic tools and risk stratification methods to distinguish between clinically significant and indolent cancers. Furthermore, Dr. Van Poppel emphasizes the role of public health education and awareness campaigns in promoting the benefits of organized screening.

Read More

Welcome and Opening Remarks

Faina Shtern, MD, underscores the rapid progress in precision medicine. This approach, she notes, is revolutionizing prostate cancer diagnosis and treatment, leading to effective and personalized patient care.

In her remarks, Dr. Shtern reflects on the achievements and milestones reached in prostate cancer research and treatment. She acknowledges the contributions of the global medical community and the importance of interdisciplinary efforts in driving innovation and improving patient outcomes. She also highlights the ongoing challenges and areas where further research and development are needed to overcome obstacles in prostate cancer care.

She stresses the need for continued research and the integration of new technologies, such as artificial intelligence and advanced imaging techniques, to further enhance diagnostic accuracy and therapeutic outcomes.

Read More

Embracing a New Normal of Innovation: Radiation Oncology Advances in Precision Diagnosis and Treatment for Prostate Cancer

Steven E. Finkelstein, MD, FACRO, examines the advances in radiation oncology that are reshaping precision diagnosis and treatment for prostate cancer. He highlights how recent technological developments have enhanced both the accuracy and effectiveness of radiation therapy.

Dr. Finkelstein discusses cutting-edge imaging techniques such as multiparametric MRI and PET/CT scans, which enable clinicians to precisely delineate tumor boundaries and identify regions of aggressive disease. He also explores advancements in radiation delivery techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT).

The presentation addresses the role of artificial intelligence (AI) and machine learning in revolutionizing radiation oncology. AI algorithms are being developed to assist in treatment planning, predict patient responses, and adapt therapies based on tumor changes. These technologies promise to streamline workflows, reduce planning times, and enhance the precision of radiation delivery.

Read More

Role of Lymphadenectomy in the Surgical Treatment of Clinical Localized Prostate Cancer

Mohamad E. Allaf, MD, discusses the use cases for lymphadenectomy in the surgical treatment of clinically localized prostate cancer. Dr. Allaf begins by addressing the rationale for performing lymphadenectomy, emphasizing its diagnostic and therapeutic potential in prostate cancer management.

A central focus of the presentation is the debate surrounding lymphadenectomy and its implications for patient outcomes. Dr. Allaf reviews the current evidence, highlighting studies that suggest extended lymphadenectomy may provide superior oncologic control by increasing the likelihood of detecting metastatic nodes in high- and intermediate-risk patients. Dr. Allaf also delves into the nuances of patient selection and determining when and how to integrate lymphadenectomy into the surgical treatment of prostate cancer.

Read More

Join the GRU Community

- Why Join? -